CMTM2 and cancer: Given the putative pivotal roles of C1Q+ TAMs, CMTM2+ TANs, and MUC1+ cancer cells in mediating treatment resistance, the DREIMT tool was used to prioritize the potential drugs targeting them (Figure S17A–F).